Literature DB >> 7648984

Prognosis and life expectancy in chronic liver disease.

A Propst1, T Propst, G Zangerl, D Ofner, G Judmaier, W Vogel.   

Abstract

The aim of the present was to define prognosis and life expectancy in patients with chronic liver disease of different etiologies and to relate them to an age- and sex-matched normal population. After a follow-up of 15 years, life expectancy of 620 patients with chronic liver disease was retrospectively calculated and compared with an age- and sex-matched normal population. Among patients with cirrhosis, prognosis was dependent upon Child classification (P = 0.001). Patients with alcoholic cirrhosis and fatty liver disease were younger (P = 0.01) and had a lower life expectancy than patients with other causes of chronic liver disease (P = 0.004). Patients with hepatitis B and hepatitis C cirrhosis showed a comparable prognosis and a significantly lower life expectancy than the age- and sex-matched population. Cryptogenic and autoimmune liver diseases showed a comparable life expectancy but a significantly shorter life expectancy than the normal population. In patients with alpha 1-antitrypsin deficiency-associated cirrhosis, a high viral coinfection rate was found (P = 0.01). For patients with noncirrhotic hemochromatosis, prognosis was poorer than that for the age- and sex-matched population. In patients with asymptomatic primary biliary cirrhosis, chronic persistent hepatitis B, and alpha 1-antitrypsin deficiency without cirrhosis, life expectancy was equal to that of the normal population. Prognosis and life expectancy in chronic liver disease depend on stage, cause, and symptoms of chronic liver disease; age; and possibilities of treatment. In patients with hereditary liver disease, additional viral infection of alcohol abuse lead to a significant deterioration of life expectancy. Patients with alcoholic chronic liver disease have the poorest prognosis.

Entities:  

Mesh:

Year:  1995        PMID: 7648984     DOI: 10.1007/bf02212706

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

1.  Antibodies to hepatitis C virus in community-acquired acute non-A, non-B hepatitis.

Authors:  F Bortolotti; A Tagger; P Cadrobbi; C Crivellaro; F Pregliasco; M L Ribero; A Alberti
Journal:  J Hepatol       Date:  1991-03       Impact factor: 25.083

2.  Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease.

Authors:  W J Powell; G Klatskin
Journal:  Am J Med       Date:  1968-03       Impact factor: 4.965

3.  Report of Nomenclature Meeting for alpha 1-antitrypsin, INSERM, Rouen/Bois-Guillaume-1978.

Authors:  D W Cox; A M Johnson; M K Fagerhol
Journal:  Hum Genet       Date:  1980       Impact factor: 4.132

4.  European livers.

Authors:  S Sherlock
Journal:  Lancet       Date:  1993-11-06       Impact factor: 79.321

5.  Alcoholic liver disease: evaluation of natural history and prognostic factors.

Authors:  S Schenker
Journal:  Hepatology       Date:  1984 Jan-Feb       Impact factor: 17.425

6.  Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis.

Authors:  A J Czaja; J E Hay; J Rakela
Journal:  Mayo Clin Proc       Date:  1990-01       Impact factor: 7.616

7.  Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis.

Authors:  A J Czaja; M P Manns; H A Homburger
Journal:  Gastroenterology       Date:  1992-10       Impact factor: 22.682

8.  Prevalence of antibodies to hepatitis C virus among patients with cryptogenic chronic hepatitis and cirrhosis.

Authors:  L J Jeffers; F Hasan; M De Medina; R Reddy; T Parker; M Silva; L Mendez; E R Schiff; M Manns; M Houghton
Journal:  Hepatology       Date:  1992-02       Impact factor: 17.425

9.  The nature and prognosis of severe cryptogenic chronic active hepatitis.

Authors:  A J Czaja; H A Carpenter; P J Santrach; S B Moore; H A Homburger
Journal:  Gastroenterology       Date:  1993-06       Impact factor: 22.682

10.  Survival and causes of death in hemochromatosis. Observations in 163 patients.

Authors:  G Strohmeyer; C Niederau; W Stremmel
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

View more
  20 in total

1.  Predicting utility of a model for end stage liver disease in alcoholic liver disease.

Authors:  Aspasia S Soultati; Spyridon P Dourakis; Alexandra Alexopoulou; Melanie Deutsch; Larissa Vasilieva; Athanasios J Archimandritis
Journal:  World J Gastroenterol       Date:  2006-07-07       Impact factor: 5.742

2.  Current Indications and Long-Term Outcomes of Surgical Portosystemic Shunts in Adults.

Authors:  Indrani Sen; Lavanya Yohanathan; Jussi M Kärkkäinen; David M Nagorney
Journal:  J Gastrointest Surg       Date:  2020-05-18       Impact factor: 3.452

3.  Model for End-Stage Liver Disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis.

Authors:  Patrick G Northup; Ryan C Wanamaker; Vanessa D Lee; Reid B Adams; Carl L Berg
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

4.  Variceal recurrence, rebleeding, and survival after endoscopic injection sclerotherapy in 287 alcoholic cirrhotic patients with bleeding esophageal varices.

Authors:  Jake E J Krige; Urda K Kotze; Philippus C Bornman; John M Shaw; Michael Klipin
Journal:  Ann Surg       Date:  2006-11       Impact factor: 12.969

Review 5.  Steatosis as a risk factor in liver surgery.

Authors:  Reeta Veteläinen; Arlène van Vliet; Dirk J Gouma; Thomas M van Gulik
Journal:  Ann Surg       Date:  2007-01       Impact factor: 12.969

Review 6.  Preventive care in chronic liver disease.

Authors:  T R Riley; J P Smith
Journal:  J Gen Intern Med       Date:  1999-11       Impact factor: 5.128

7.  The Royal Free Hospital-Nutritional Prioritizing Tool Is an Independent Predictor of Deterioration of Liver Function and Survival in Cirrhosis.

Authors:  Sarah Maria Borhofen; Carmen Gerner; Jennifer Lehmann; Rolf Fimmers; Jan Görtzen; Beate Hey; Franziska Geiser; Christian P Strassburg; Jonel Trebicka
Journal:  Dig Dis Sci       Date:  2016-01-02       Impact factor: 3.199

8.  Treatment of alcoholic liver disease.

Authors:  Thomas H Frazier; Abigail M Stocker; Nicole A Kershner; Luis S Marsano; Craig J McClain
Journal:  Therap Adv Gastroenterol       Date:  2011-01       Impact factor: 4.409

9.  Effect of body mass index on nonalcoholic fatty liver disease in patients undergoing minimally invasive bariatric surgery.

Authors:  Constantine T Frantzides; Mark A Carlson; Ronald E Moore; John G Zografakis; Atul K Madan; Susan Puumala; Ali Keshavarzian
Journal:  J Gastrointest Surg       Date:  2004-11       Impact factor: 3.452

Review 10.  Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease.

Authors:  Shane J Mills; Stephen A Harrison
Journal:  Curr Gastroenterol Rep       Date:  2005-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.